This is a double-blind, placebo-controlled, multicenter, efficacy and safety study of
firibastat (QGC001) administered po bid over 12 weeks in male and female subjects ≥18 years
of age at Screening, with uncontrolled primary HTN. Subjects will be randomized 1:1 to
investigational product (IP) and will receive either firibastat (QGC001) or matching placebo
on top of their current chronic antihypertensive treatments.